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ME1036, a novel parenteral carbapenem, was developed for the treatment of MRSA and 
vancomycin-intermediate S. aureus (VISA). 
A model of hematogenous pulmonary infection was induced in mice by tail vein injection of 
MRSA strain NUMR10 or VISA Mu50 enmeshed in agar beads. Twenty-four h after 
infection, mice were treated twice daily for 7 days with 20 mg/kg/day vancomycin or 
ME1036. Mice infected with VISA were also pretreated with cyclophosphamide to induce an 
immunocompromised state. Twelve h after the final drug treatment, the number of viable 
bacteria in the lungs was counted.  
VCM decreased the number of viable MRSA in the lungs in comparison with the control, 
although the difference was not significant (log10 cfu/lung [mean±SEM] = 6.876±0.54 and 
8.25±0.41, respectively). In contrast, treatment with ME1036 resulted in a significant 
decrease (log10 cfu/lung= 2.69±0.44 [n=6]; P<0.0001) in the number of viable MRSA 
compared with both the VCM-treated and control mice. In the VISA-infected mice, ME1036 
significantly reduced the number of viable bacteria compared to VCM and control (log10 
cfu/lung = 3.65±0.68 for ME1036 vs. 5.71±0.75 for VCM [P<0.05] and 7.07±0.45 for control 
[P<0.001]).  
ME1036 produced >3 log10 reduction versus control against both MRSA strains: >5 log for 
the vancomycin-susceptible and 3.4 log for the VISA, whereas vancomycin produced <1.3 
log for both strains. 
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INTRODUCTION 
Methicillin-resistant Staphylococcus aureus (MRSA) was first identified in the 1960s, 
and the acquisition by MSSA of genes encoding an additional penicillin-binding protein, 
PBP-2a, which has a low affinity for -lactams, resulted in the emergence of MRSA in many 
health care institutions around the world. Currently, glycopeptides such as vancomycin 
(VCM) and teicoplanin still provide effective therapy against most strains of MRSA. 
However, the first MRSA to acquire resistance to VCM was isolated from a Japanese patient 
in 1996 [1]. Subsequent isolation of several VCM-intermediate S. aureus (VISA) strains from 
USA, France, Korea, South Africa, and Brazil has confirmed that emergence of VCM 
resistance in S. aureus is a global issue [2]. Subsequently, new agents against MRSA and 
VISA were developed, including linezolid, daptomycin, and quinupristin-dalfopristin. 
ME1036, a novel parenteral carbapenem, was developed to combat MRSA or VISA [3-4], 
and it is expected to be useful for the treatment of severe staphylococcal infections such as 
pneumonia, bacteremia, and pulmonary abscesses.  
To evaluate the efficacy of antibacterial agents and the pathogenesis of blood-borne 
staphylococcal pneumonia, we previously established a murine model of pulmonary infection, 
wherein infection is induced by the intravenous injection of agar-enmeshed S. aureus [5-8]. 
The aims of the present study were to compare the activity of ME1036 with VCM against 
pulmonary infection caused by MRSA and VISA and to analyze the antibacterial and 
histopathological effects and the pharmacokinetics of ME1036. 
 
MATERIALS AND METHODS 
 
Laboratory animals 
Six-week-old male ddY specific pathogen-free mice (25–30 g body weight) were purchased 
from Shizuoka Agricultural Cooperative Association Laboratory Animals (Shizuoka, Japan). 
All animals were housed at the Laboratory Animal Centre for Biomedical Science at 
Nagasaki University in a pathogen-free environment and received sterile food and water. All 
experimental protocols were approved by the Ethics Review Committee for Animal 
Experimentation at our institution. 
 
Bacterial strain 
Two strains of S. aureus were examined. Strain NUMR101 was isolated at Nagasaki 
University Hospital from the blood of an inpatient with pneumonia. Mu50, a VISA strain, 
was kindly provided by K. Hiramatsu (Juntendo University, Tokyo, Japan). The bacteria were 
stored at −70°C in brain-heart infusion broth (BBL Microbiology System, Cockeysville, MD) 
supplemented with 10% (v/v) glycerol and 5% (w/v) skim milk (Yukijirushi Co., Tokyo, 
Japan) until use. 
 
Determination of minimum inhibitory concentrations (MICs) 
ME1036 (Meiji Pharmaceutical Co., Tokyo, Japan) was dissolved in 0.01 N NaOH, 2% 
glucose, and 1 mM phosphate-buffered saline. VCM (Shionogi Pharmaceutical Co., Osaka, 
Japan) was dissolved in sterile water immediately before use. The MIC of each agent was 
determined by the microplate dilution technique using Muller-Hinton medium, with an 
inoculum size of 5  105 colony forming units (cfu)/ml. The MIC was defined as the lowest 
concentration of the test agent that inhibited visible growth of bacteria after 18 h at 37°C. The 
MICs of ME1036 and VCM for NUMR101 were both 1.0 g/ml, and those for Mu50 were 
2.0 and 8.0 g/ml, respectively. 
 
Mouse model of hematogenous pneumonia  
The mouse model of hematogenous pneumonia and the method of inoculation were 
previously described [5-8]. Briefly, S. aureus was cultured on trypticase soy agar (BBL 
Microbiology System, Cockeysville, MD)-based sheep blood agar plates for 24 h at 37°C. 
Bacteria were suspended in endotoxin-free sterile saline and harvested by centrifugation 
(3000 × g; 4°C; 10 min). The organisms were resuspended in cold sterile saline and diluted to 
2 × 109 to 4 × 109 cfu/ml, as estimated by turbidimetry. The numbers of bacteria were 
verified by inoculating duplicates of serial dilutions onto blood agar plates and counting the 
cfu after 48 h at 37°C. The suspension was warmed to 45°C, and 10 ml of the suspension was 
mixed with 10 ml of 4% (w/v) molten Noble agar (Difco Laboratories Detroit, MI) at 45°C. 
The agar-bacterium suspension (1.0 ml) was placed in a 1.0-ml syringe, and the suspension 
was rapidly injected through a 26-gauge needle into 49 ml of rapidly stirred ice-cooled sterile 
saline. This resulted in solidification of the agar droplets into beads approximately 200 μm in 
diameter. The final concentration of agar was 0.04% (w/v), and the final number of bacteria 
was 2 × 107 to 4 × 107 cfu/ml. Mice infected with VISA were pretreated with 
cyclophosphamide at Day -3 and at Day -1 before inoculation to induce an 
immunocompromised state. Mice were injected in the tail vein with 0.20 to 0.25 ml (10 ml/g 
of body weight) of the suspension of bacteria enmeshed in agar beads at Day 0. Treatment 
started at day 1 and ended at day 7.  
Treatments 
Mice infected with MRSA were treated every day for 7 days by intraperitoneal injection of 
ME1036 (200 mg/kg/day, bid; n=6), VCM (200 mg/kg/day, bid; n=6), or saline (control; 
n=6). Mice infected with VISA were treated every day for 10 days by intraperitoneal 
injection of ME1036 (100 mg/kg/day, bid; n=6), VCM (100 mg/kg/day, bid; n=6), or saline 
(control; n=6). Twelve h after the final drug treatment, mice were sacrificed and the number 
of viable bacteria in the lungs was counted. 
 
Bacteriological and histopathologica, analyses 
Each group of animals was sacrificed by cervical dislocation at twelve h after the final drug 
treatment. After exsanguination, the lungs were dissected and removed under aseptic 
conditions. Organs used for bacteriological analyses were homogenized and cultured 
quantitatively by serial dilutions on blood agar plates. Lung tissue for histological 
examination was fixed in 10% buffered formalin and stained with hematoxylin-eosin. The 
histological analysis only performed in the VISA-infected animals. 
 
Measurement of the lung and serum concentrations of drugs  
Mice (n=4 per group) were sacrificed by cervical dislocation 0.25, 0.5, 1, 2, 4, and 6 h after 
the completion of treatment. Serum was separated after the blood had clotted. The infected 
mice were used for the measurement of lung and serum concentrations. They were different 
from those for bacteriological and hitopathological analyses. There are 6 timepoints and 4 
animals per group, were 24 animals (6x4) used per treatment group. The lungs were removed, 
washed briefly, and cryohomogenized with saline. These samples were immediately frozen 
and stored at −80C for a few days until the assay was performed. The concentration of 
ME1036 was measured by the paper disc (bioassay) method. The test organism was Bacillus 
subtilis ATCC6633. The concentrations of VCM were measured by fluorescence polarization 
immunoassay [9]. The pharmacokinetic parameters were calculated on the basis of 
non-compartment model and 1-compartment model with the software; WinNonlin(Ver.5.0, 
Pharsight Corporation). The PK/PD parameters were calculated with Microsoft Excel. The 




Bacteriological data were expressed as means ± SEM. Survival data were expressed by 
Kaplan-Meyer analysis. Differences between groups were examined for statistical 
significance using an unpaired t-test. A P value of less than 0.05 was considered to indicate a 




Therapeutic effects of antibacterial agents 
Treatment with VCM decreased the number of viable MRSA in the lungs in comparison with 
the control without any significance (log10 cfu/lung [mean±SEM] = 6.876±0.54 and 
8.25±0.41, respectively [n=6 per group]). In contrast, treatment with ME1036 (log10 
cfu/lung= 2.69±0.44 [n=6]) resulted in a significant decrease (P<0.0001) in the number of 
viable MRSA compared with both the VCM-treated and control mice (Fig. 1A). In the 
VISA-infected mice, ME1036 significantly reduced the number of viable bacteria compared 
to VCM and control (log10 cfu/lung = 3.65±0.68 for ME1036 vs. 5.71±0.75 for VCM 
[P<0.05] and 7.07±0.45 for control [P<0.001] [n = 6 per group]; Fig. 1B). The figures refer 
to absolute colony counts. 
Histopathological examination 
Lung specimens of mice infected with VISA Mu50 were examined 7 days after treatment. 
The lungs showed abscesses consisting of a central zone of a bacterial colony with infiltrating 
acute inflammatory cells (Fig. 2). The ME1036-treated (Fig. 2A) and VCM-treated groups 
(Fig. 2B) exhibited fewer abscesses and less inflammation than the control group (Fig. 2C). 
Fewer abscesses were observed in the ME1036 group. 
 
Serum and lung ME1036 and VCM concentrations  
The peak concentrations of ME1036 and VCM were 78.71 and 61.03 g/ml in plasma and 
20.03 and 26.19 g/g in lung tissues, respectively (Fig. 3). Table 1 shows the 




In the current studies, we used a mouse model hematogenous pulmonary infection to assess 
the effects of ME1036 on MRSA and VISA. This model is considered to accurately reflect 
the efficacy of antimicrobial agents against pulmonary infection with MRSA and VISA. 
Using this model, we previously showed the efficacy of linezolid (the first oxazolidinone 
agent), DX-619 (a new quinolone agent), and quinupristin-dalfopristin (a complex of 
streptogramin A and B) against MRSA and VISA, whereas VCM was consistently ineffective 
in this model.5,7,8 In the present study, measurement of bacterial numbers and 
histopathological analyses revealed that ME1036 was more effective than VCM in the MRSA 
and VISA lung infection models. 
When the level of protein binding is taken into account, the free-fraction areas under the 
concentration-time curve between 0 and infinite hours were similar for ME1036 and VCM. 
The data obtained from these pharmacokinetic studies, however, cannot account for the 
superior efficacy of ME1036 in this model.  
In the previous rabbit model, the bacterial counts in the controls were in the same range. The 
MIC for the inoculum size (1.6 × 107 CFU/spot) was comparable to the bacterial counts 
within the vegetation in this model. The MIC of ME1036 at the larger inoculum size was 
lower than that of vancomycin. The sub-MIC effect and the MIC observed at large inoculum 
sizes may contribute to the better in vivo efficacy of ME1036 compared to that of 
vancomycin.[4]. 
In conclusion, we showed that ME1036, a novel parenteral carbapenem, can reduce 
the number of bacteria in a MRSA hematogenous infection mouse model and that it is 
significantly more effective than VCM at improving the survival rate of 
immunocompromized mice infected with VISA. Thus, it is likely that ME1036 will be 
clinically effective for treating MRSA and VISA infections. 
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FIGURE LEGENDS 
 
Figure 1. Effects of ME1036 and VCM on the bacterial numbers in lungs of animals with 
VISA hematogenous pulmonary infection. Mice were treated with each agent after infection.  
ME1036 produced >3 log10 reduction versus control against both MRSA strains: >5 log for 
the vancomycin-susceptible and 3.4 log for the VISA, whereas vancomycin produced <1.3 
log for both strains. 
Figure 2. Histopathological examination of lung specimens from mice sacrificed three days 
after treatment. (hematoxylin and eosin staining; original magnification, 50). (A) 
ME1036-treated mice. (B) VCM-treated mice. (C) Control. Note that the inflammatory 
process is less severe in the ME1036-treated group than in the other groups. 
 
Figure 3. Pharmacokinetics of ME1036 (100 mg/kg/day) (A) and VCM (100 mg/kg/day) (B) 
in the lungs of infected mice. Drugs were administered intraperitoneally twice daily starting 
24 h after infection. Results are presented as means±SD.  
Table 1. Selected pharmacokinetic and pharmacodynamic parameters for mean profiles for ME1036 and VCM in the serum and lung of infected mice.
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Pharmacokinetic data from MRSA-infected mice treated with each drug at 100 mg/kg once a day after bacterial inoculation. Pharmacokinetic parameters were calculated 
from the arithmetic means of plasma and lung concentrations (mean values for four animals)             . 
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